Trials in Glendale, Arizona
Here are the top 10 medical studies for lung cancer in Glendale, Arizona
Popular Filters
Phase 3 Trials
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Tyrosine Kinase Inhibitor
Alectinib vs Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial compares two medications, alectinib and crizotinib, for treating a specific type of advanced lung cancer. The patients have not received any prior treatment for their cancer. Both drugs work by blocking a protein that helps the cancer cells grow. Alectinib has shown superior effectiveness and fewer side effects compared to crizotinib in treating this type of lung cancer.
Monoclonal Antibodies
Pembrolizumab + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial will see if a new cancer treatment is better than current treatments. The new treatment is pembrolizumab (MK-3475) given before and after surgery for people with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC).
Trials With No Placebo
Checkpoint Inhibitor
Immunotherapy + Radiation for Colorectal and Lung Cancer
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing the side effects of two immunotherapies, durvalumab and tremelimumab, in combination with high or low-dose radiation therapy, in treating patients with metastatic colorectal or non-small cell lung cancer.
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
PD-L1 Inhibitor
Durvalumab for Lung Cancer
Recruiting1 awardPhase 2
Goodyear, Arizona
This trial will study the effects of the drug durvalumab in patients with non small cell lung cancer that has spread to other parts of the body. The trial will assess how well the drug works, as well as its safety and tolerability.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.